Advertisement

Topics

Latest "Aphton Corporation" News Stories

12:26 EST 19th November 2018 | BioPortfolio

Here are the most relevant search results for "Aphton Corporation" found in our extensive news archives from over 250 global news sources.

More Information about Aphton Corporation on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Aphton Corporation for you to read. Along with our medical data and news we also list Aphton Corporation Clinical Trials, which are updated daily. BioPortfolio also has a large database of Aphton Corporation Companies for you to search.

Showing "Aphton Corporation" News Articles 1–25 of 527

Monday 19th November 2018

ESPERITE (ESP) announces publication of its Annual Report 2017 before 24 November 2018

Amsterdam, The Netherlands - 19 November 2018 Esperite announces that the preparation of its Annual Report 2017 is now under final review by its auditors and should be published before 24 November 2018. About ESPERITEESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.To learn more abou...


SANYEI CORPORATION Based in Japan Launches ION-Sei™ into the UK Market in Time for the Christmas Season. A Unique Electric Toothbrush That Uses Patented Technology to Suppress Bacteria That Cause Plaque and Gum Disease

Patented innovative and unique technology, that works by using UV light, a Titanium Dioxide (TiO2) rod, Water, generating electrons and ions, creating a longer lasting, deeper clean Japanese Technology combined with contemporary German Design, creates an elegant but functional electric toothbrush Very effective,...

Active Biotech's election committee appointed

PRESS RELEASE In accordance with a decision made by the Annual General Meeting held on May 17, 2018, the Election Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2018, and the Chairman of the Board. For the 2019 Annual General Meeting, the Election Committee shall propose Board members and a Chairman of the Boa...


GENFIT ANNOUNCES PLANS TO CONDUCT REGISTERED PUBLIC OFFERING IN THE UNITED STATES

FOR IMMEDIATE RELEASE GENFIT ANNOUNCES PLANS TO CONDUCT REGISTERED PUBLIC OFFERING IN THE UNITED STATES Lille (France), Cambridge (Massachusetts, United States), November 19, 2018 - GENFIT SA (Euronext: GNFT), a French biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabo...

Sunday 18th November 2018

Fortress Biotech Announces Agreement to Sell Its Majority Stake in National Holdings Corporation to NHC Holdings, LLC, a wholly-owned subsidiary of B. Riley Financial

NEW YORK, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that it has entered into an agreement to sell its 56.1 percent majority stake of National Holdings Corporation (NASDAQ: NHLD) (“National”), a lea...

Arrayit Corporation Announces Allergy Testing Agreement with Sutter Health

Sunnyvale, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces an allergy testing agreement with Northern California healthcare leader Sutter Health. The company is providing its proprietary microarray-based finger stick allergy testing services to Sutter Health via doctors in the Sutter Health-affiliated Palo Alto Med...

Friday 16th November 2018

FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication

Novartis International AG / FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Promacta receives FDA approval for first-line treatment of severe aplastic anemia (SAA) and Breakthro...

New Findings Presented at the VEITHsymposium Reiterate Consistent, Durable Outcomes in Complex Aortic Disease with Heli-FX(TM) Endoanchor(TM) System

Three-Year Data from the ANCHOR Registry Reiterate Applicability in Patients with Hostile Aortic Neck Anatomies DUBLIN and NEW YORK - November 16, 2018 - Medtronic plc (NYSE:MDT) today announced new data on the Heli-FX(TM) EndoAnchor(TM) system, which demonstrated durability, safety and efficacy in patients with complex aortic abdominal aneurysm (AAA) anatomy, particularly those ...

Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer

Novartis International AG / Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Kisqali is the CDK4/6 inhibitor with the ...

Sanofi: European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness

European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness The positive opinion is the result of a 10-year partnership between the Drugs for Neglected Diseases initiative (DNDi), Sanofi and African partners Fexinidazole will support international efforts to eliminate sleeping sickness, a

LIDDS participates at Redeye Life Science Day

The Life Science Event takes place at Haymarket by Scandic on November 21. CEO Monica Wallter will present the company and update the audience on the latest developments of the NanoZolid technology platform. The LIDDS presentation goes live at 10.20 and can be followed on the following link: www.redeye.se/live/lsday-2018The video can also be viewed later at www.redeye.se/live/ls-day-2018 or...

LIDDS presence at BIO-Europe 2018 to focus on NanoZolid's broad drug formulation capability

The Life Science Event takes place at Haymarket by Scandic on November 21. CEO Monica Wallter will present the company and update the audience on the latest developments of the NanoZolid technology platform. The LIDDS presentation goes live at 10.20 and can be followed on the following link: www.redeye.se/live/lsday-2018The video can also be viewed later at www.redeye.se/live/ls-day-2018 ...

Immunicum AB (publ) Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study

Press Release 16 November 2018 Immunicum AB (publ) Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study Immunicum AB (publ; IMMU.ST) announced today that it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate its lead ...

Xbrane Biopharma releases interim report for the third quarter of 2018

Press release2018-11-16   Xbrane Biopharma AB's (publ.) ("Xbrane") interim report for the third quarter of 2018 is now available on the Company's website, www.xbrane.com. Financial summary third quarter 2018 Revenue amounted to SEK 2,441 thousand (-). Gross margin amounted to 21% (-). Other operating income amounted to SEK 84,041 thousand (331), of w

DBV Technologies Appoints Daniel Tassé as Chief Executive Officer

Montrouge, France, November 16, 2018 DBV Technologies Appoints Daniel Tassé as Chief Executive Officer Daniel brings strong track record of building and leading global organizations and delivering transformative products to patients Co-founder Dr. Pierre-Henri Benhamou to retire as CEO and serve as Non-Executive Chairman of the Board DBV Technologies ...

Thursday 15th November 2018

ERYTECH Partners with New York Blood Center for Red Blood Cell Supply and Research

LYON, France and CAMBRIDGE, Mass., Nov. 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced a strategic partnership with New York Blood Center (NYBC) for red blood cell supply and research. The partnership encompasses N...

SPINEWAY :Spineway sets up the governing structure for its US subsidiary

Press release                                                                                                                                                                 Ecully, 15 November 2018 Spineway sets up the gove...

Aradigm Announces Third Quarter 2018 Financial Results

Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2018. Third Quarter 2018 Financial Results The Company recorded $282,000 in revenue in the third quarter of 2018 compared with $2.7 million in revenue in the third quarter of 2017. The ...

INNATE PHARMA : Third quarter 2018 report

Innate Pharma Third quarter 2018 Report Acceleration of becoming a fully integrated oncology-focused biotech company through a recent landmark deal with AstraZeneca Expansion of oncology development collaboration with AstraZeneca validates Innate's leadership in immuno-oncology discovery Strengthens financial runway by $242 million in total near-term cash proceeds

Wednesday 14th November 2018

International Stem Cell Corporation Announces Strong Financial Results for the Three and Nine-Months ended September 30, 2018

Increases in Revenues and Profit MarginsNet Income Realized for the Quarter CARLSBAD, Calif., Nov. 15, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and...

Active Biotech AB - Interim report January - September 2018

                                  Third quarter in brief Active Biotech provides update on laquinimod in Huntington's disease Active Biotech regains global rights to the development and commercialization of laquinimod Data from the LEGATO-HD study of laquinimod in Huntington's disease presented at the EHDN meeting Events after t...

Virbac: Availability of the quarterly financial information as of September 30, 2018

Virbac: Availability of the quarterly financial information as of September 30, 2018 Public release - November 14, 2018 The quarterly financial information as of September 30, 2018 is available: ·           on our website: corporate.virbac.com under the section Investors - Financial reports - 2018;·           or on request, under legal and regulatory conditions. ...

Terveystalo Plc: Financial calendar and AGM in 2019

Terveystalo Plc Stock Exchange Release 14 November 2018 at 09:05 a.m. EET In 2019, Terveystalo Plc will publish financial reports as follows: Financial Statements Bulletin 2018 on Thursday, February 14, 2019 Annual Report 2018 on week 9, 2019 Interim report for January-March 2019 on Thursday, May 9, 2019 Half-Year Report for January-June 2019 on Thursday, August 8, 20...

Customer evaluation of CADScor®System compares favorably against existing methods

Interim Report, January - September 2018 Malmö, November 14, 2018 Customer evaluation of CADScor®System compares favorably against existing methods "During the quarter we proudly reported that Kristianstad Central Hospital in Sweden evaluated the CADScor®System with a positive outcome. Due to the good result the hospitals clinical management team has now included the CADScor®Sy...

Terveystalo Group Interim Report 1 January - 30 September 2018

Terveystalo Plc. Interim report 14 November 2018 at 9:00 a.m. EET Strong earnings trend continued July-September 2018 in brief Revenue increased by 3.2 percent year-on-year to EUR 160.3 million (155.4)  Adjusted* EBITDA increased by 15.2 percent year-on-year to EUR 20.1 million (17.5)  EBITDA more than tripled year-on-year to EUR 27.6 million (7.6)  Adjusted* earni...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks